• Users Online: 415
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2012  |  Volume : 37  |  Issue : 2  |  Page : 81-87

Association between 4G/4G plasminogen activator inhibitor-1 polymorphism, PAI-1 activity, and diabetic retinopathy


1 Department of Clinical and Chemical Pathology, Fayoum University, Fayoum, Egypt
2 Department of Clinical and Chemical Pathology, Suez Canal University, Ismailia, Egypt
3 Department of Medical Molecular Genetics, Research Institute of Ophthalmology, Cairo, Egypt
4 National Research Centre, Ophthalmic Genetics, Research Institute of Ophthalmology, Cairo, Egypt
5 Department of Biochemistry and Ophthalmic, Research Institute of Ophthalmology, Cairo, Egypt

Correspondence Address:
Hoiyda A. Abdel Rasol
Department of Clinical and Chemical Pathology, Fayoum University, Fayoum
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.7123/01.EJH.0000415057.95581.7c

Rights and Permissions

Background

Plasminogen activator inhibitor-1 (PAI-1) is a key regulator of fibrinolysis; however, the relationship between PAI-1 and the most common diabetic microvascular complication, retinopathy, is unclear.

Objectives

To examine the association between the 4G/4G polymorphism of the PAI-1 gene with diabetic retinopathy (DR) as well as with the plasma levels of the PAI-1 enzyme among Egyptian patients.

Participants and methods

Thirty-three patients who had type 2 diabetes for more than 10 years were compared with 63 patients with proliferative diabetic retinopathy (PDR). Both groups were compared with 48 control individuals. All groups were matched for age and sex. PAI-1 4G/5G genotyping was carried out by a PCR and the PAI-1 levels were measured by enzyme-linked immunosorbent assay testing.

Results

Higher plasma PAI-1 activity was associated with a higher risk of DR. The overall frequency of the 4G allele was 54.54% among type 2 diabetes patients versus 78.79% among PDR patients (P<0.01). Using multivariate logistic regression analyses, patients with PDR had a higher representation of the genotype 4G/4G (P<0.05, odds ratio: 3.15, 95% confidence interval 0.13–0.89) and the 4G/4G patients studied had higher plasma levels of PAI-1 activity.

Conclusion

The PAI-1 gene polymorphism 4G/4G contributed to the genetic susceptibility to DR and a higher PAI-1 plasma level was independently associated with a higher risk of retinopathy among Egyptians.



[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1454    
    Printed22    
    Emailed0    
    PDF Downloaded82    
    Comments [Add]    

Recommend this journal